ğŸ“ˆ $COR SMA (8/26) cross just fired: 2.87 reward/risk ratio meets GLP-1 drug boom driving 36% YoY growth - rare combo of math edge + mega catalyst.
Here's why this signal matters. ğŸ‘‡

âœ… Strategy Performance ($COR, dual SMA (8/26) cross, 14.7 years)
â€¢ Win Rate: 45% (75 trades)
â€¢ Net Performance: +373.6%
â€¢ Avg Win/Loss: +9.83% / -3.43%
â€¢ Reward/Risk Ratio: 2.87
â€¢ Max Drawdown: -42.5% (vs B&H: -40.9%)
â€¢ Sharpe: 0.62 | Sortino: 1.33
â€¢ Exposure: 60.2% | Avg Trade: 29 days
â€¢ Expectancy: $0.70 per $1 risked

ğŸ“… Seasonality Edge (15 years)
June timing: Strong (67% historical avg)
â€¢ Best months: Jan (87%), Oct (80%), Sep (73%) avg performance
â€¢ Worst months: Jul (43%), Apr (47%) avg performance
â€¢ Current month (June): 67% historical avg, 57% mean change
â€¢ Pattern strength: Consistent positive bias, strong Q4 performance

ğŸ” Why This Signal Triggered TODAY
â€¢ Entry Condition: SMA (8/26) crossover signal confirmed
â€¢ Technical Setup: Bullish ascending triangle breakout complete
â€¢ Fundamental Catalyst: GLP-1 drugs (Ozempic/Wegovy) driving 30% of enterprise growth
â€¢ Market Context: Outperforming SPY, defensive healthcare positioning
â€¢ Risk Management: Low beta (0.44), strong seasonality support through summer

ğŸ“Š $COR Fundamentals
â€¢ Fortune #10 pharma distributor, $310B+ annual revenue
â€¢ Price Target: $325 (10% upside), 17.15x forward P/E
â€¢ Strategic M&A: $4.6B RCA acquisition expands specialty pharma reach

ğŸ“Œ Bottom Line
Strategy with 373.6% historical returns just triggered entry signal. June strong seasonality (67%) + ascending triangle breakout + GLP-1 mega-trend align for compelling risk/reward setup.

Time to act on this live signal. ğŸ¯

#COR #trading #livesignal #seasonality #investing
